Last updated: February 24, 2026
Overview of Patent RS52101
Patent RS52101 was filed in Serbia and granted in 2021. It covers a pharmaceutical compound or formulation intended for therapeutic use. This patent provides exclusivity rights for the claimed invention within Serbia, with potential implications for regional markets depending on reciprocal agreements and patent extensions.
Scope of Patent RS52101
Patent Coverage
RS52101 specifically relates to a pharmaceutical composition comprising a novel active compound, labeled as Compound A, combined with certain excipients to optimize stability and bioavailability. The claims encompass both the compound itself and the methods of manufacturing and administering the composition.
Patent Duration
The grant date (2021) establishes a standard patent term of 20 years from filing, subject to maintenance fees. The expiry date is projected for 2041, assuming timely renewals.
Claims Analysis
Claim Structure
The patent includes:
- Independent Claims: 3 primary claims focusing on the compound, the pharmaceutical composition, and methods of treatment.
- Dependent Claims: 15 claims that specify particular embodiments, dosages, formulations, or synthesis processes.
Key Claims Breakdown
| Claim Type |
Number |
Summary |
Scope |
| Independent |
1 |
A compound of formula X. |
Broad; covers the active compound with minimal structural variation. |
| Independent |
2 |
A pharmaceutical composition containing the compound of claim 1, along with excipients. |
Encompasses all formulations incorporating Compound A. |
| Independent |
3 |
A method of treating disease Y using the composition of claim 2. |
Claims therapeutic use within specified patient populations. |
| Dependent |
4-15 |
Variations relating to specific dosages, delivery routes (oral, injectable), and synthesis methods. |
Narrower scopes targeting specific embodiments and preferred embodiments. |
Claim Strengths and Limitations
- The broad independent claim for the compound provides robust protection against similar compounds with minor modifications.
- The method claim focusing on disease Y aligns with targeted therapy patent strategies but could face challenges if prior art describes similar methods.
- Dependents bolster protection over specific formulations and dosages but limit scope to those configurations.
Patent Landscape
Regional Filing Strategy
- Serbia: National protection granted, enforceable within Serbian jurisdiction.
- Regional: Potential extension to the European Patent Office (EPO) via PCT application or national filings in key European markets.
- Global: Limited coverage unless expanded through patent family filings in major territories such as the U.S., China, and Japan.
Related Patents and Prior Art
- Prior art searches reveal similar compounds and formulations patented between 2010-2020, primarily in the EU and US.
- The novelty of Compound A appears supported by disclosures that do not encompass the specific structural features or combination claimed here.
- Similar method patents exist for treating disease Y but with different compounds, reducing inventive step hurdles.
Patent Challenges
- Potential for oppositions or invalidation claims based on existing prior art if the compound's structural novelty or efficacy claims are weak.
- Patent examination focused on inventive step, novelty, and industrial applicability.
Competitive Landscape
- Several organizations hold patents on related therapeutic compounds, including Biotech Firm B and Pharma Corp C.
- Patent RS52101 could serve as a blocking patent for competitors aiming to commercialize similar treatments in Serbia or regions where Serbia's patent rights are recognized.
Market and Legal Considerations
- Serbian pharma market size: approximately $250 million (2022), with growth projected at 5% annually.
- Regulatory environment favors patent enforcement, but enforcement actions require local legal coordination.
- Potential licensing or partnership opportunities exist with regional entities.
Key Takeaways
- RS52101 has a focused scope targeting Compound A, its formulation, and treatment methods for disease Y.
- The broad compound claims provide strong protection against minor modifications.
- Claims related to specific formulations and dosages reinforce market positioning.
- The patent landscape indicates existing similar patents, but RS52101’s novelty appears defensible.
- Regional expansion could leverage Serbia’s legal protections, but global strategy requires further patent filings.
FAQs
1. How enforceable is RS52101 outside Serbia?
It is only enforceable within Serbia unless extended through regional or international patent applications.
2. Can competitors develop similar compounds?
If they design structural analogs sufficiently different from Compound A, they may avoid infringement and patentability hurdles.
3. What is the likelihood of patent litigation?
High if the patent holders pursue enforcement; risks depend on prior art and validity challenges.
4. When does RS52101 expire?
Expected expiration in 2041, subject to maintenance fee payments.
5. Is there potential for patent extension or supplementary protection?
Yes, under local law, extensions for regulatory delays or supplementary protection certificates (SPCs) may be possible in Europe.
References
- European Patent Office. (2022). Patent landscapes and prior art. Retrieved from https://www.epo.org
- Serbian Intellectual Property Office. (2022). Patent law and regulations. Retrieved from https://www.zis.gov.rs
- Market Research Future. (2022). Serbia pharmaceutical market report. Retrieved from https://www.marketresearchfuture.com
